| Bid | 5.26 |
| Market Cap | 41.86M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.4 |
| PE Ratio (ttm) | 13.16 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.43 |
| Volume | 56,931 |
| Avg. Volume (20D) | 467,540 |
| Open | 5.43 |
| Previous Close | 5.38 |
| Day's Range | 5.20 - 5.54 |
| 52-Week Range | 3.61 - 19.43 |
| Beta | undefined |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is i...
Analyst Forecast
According to 3 analyst ratings, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 545.77% from the latest price.
Next Earnings Release
Analysts project revenue of $4.28M, reflecting a -39.19% YoY shrinking and earnings per share of -2.94, making a -12.24% decrease YoY.
2 months ago · businesswire.com
Precision BioSciences to Report Third Quarter Results on November 4, 2024DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
